



10 June 2026

ClearPoint Neuro, Inc.  
120 S. Sierra Ave., STE 100  
Solana Beach, CA 92075  
United States

California Institute for Regenerative Medicine  
Application Review Subcommittee

**RE: CLIN2-19526 "SRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma"**

Dear Members of the CIRM ARS,

I am writing in support of Siren Biotechnology's CIRM CLIN2-198526 grant application to address directly the concern raised by reviewers regarding patient accessibility of convection-enhanced delivery (CED). As Chief Medical Officer of ClearPoint Neuro and a UCSF neurosurgeon with extensive experience in MRI-guided CED, I am in a unique position to speak to the current state and growth trajectory of this technology, and to offer a different perspective on what the accessibility landscape actually looks like, both now and moving forward.

ClearPoint Neuro is the leading provider of MRI-guided neurosurgical platforms used for CED delivery of investigational and approved agents in the brain. Our systems are currently deployed at over 90 neurosurgical centers internationally (with clinical and research installations in North America, the EU and Asia), and our goal is to actively onboard new clinical sites each year. This growth reflects a deliberate and well-supported expansion of CED infrastructure driven by increasing clinical interest in local delivery across neuro-oncology, neuro-muscular, and neuro-degenerative indications. Importantly, the institutions adopting CED are not limited to a small cluster of elite academic centers; they include a growing number of regional medical centers and cancer programs that are investing in this capability as demand from patients and referring physicians continues to increase.

In practice, CED is now available at a broad and growing range of institutions, and the pace of adoption makes concerns about geographic confinement less applicable with each passing year. The number of sites performing CED-based clinical trials has grown substantially, and the procedural expertise required is well within reach of any neurosurgical program that invests in appropriate training, research and imaging infrastructure - which ClearPoint actively supports through our clinical education and implementation programs, as well as the CLEAR Therapy Site designation program.

ClearPoint Neuro is proud to support Siren and their SRN-101 program and to serve as the platform partner for MRI-guided CED drug delivery in this trial. I strongly endorse this CIRM CLIN2 application, and am confident in the feasibility and scalability of CED as the delivery modality for this therapy for patients everywhere.

Best regards,

A handwritten signature in black ink, appearing to read 'Paul Larson', with a long horizontal flourish extending to the right.

**Paul Larson, MD, FAANS**

*Chief Medical Officer*



Email: [plarson@clearpointneuro.com](mailto:plarson@clearpointneuro.com)  
Direct Phone #: cell 415-606-0485